<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04840914</url>
  </required_header>
  <id_info>
    <org_study_id>17518</org_study_id>
    <secondary_id>J2L-MC-EZBB</secondary_id>
    <nct_id>NCT04840914</nct_id>
  </id_info>
  <brief_title>A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction</brief_title>
  <official_title>A Single-Dose Study Evaluating Different Dose Levels and Subcutaneous Infusion Durations on Safety, Pharmacokinetics, and Pharmacodynamics of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the tolerability and safety of LY3461767 with&#xD;
      any side effects that might be associated with it. Study drug will be provided in a&#xD;
      continuous subcutaneous infusion lasting 24 hours to 96 hours, depending on the cohort. Blood&#xD;
      tests will be performed to check concentrations of LY3461767 in the bloodstream and how long&#xD;
      it takes the body to get rid of it in participants with chronic heart failure with reduced&#xD;
      ejection fraction (HFrEF). The study will last up to 3 months and may include 5 visits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">July 27, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 27, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Day 90</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3461767</measure>
    <time_frame>Predose up to 48 hours post end of infusion</time_frame>
    <description>PK: AUC of LY3461767</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of LY3461767</measure>
    <time_frame>Predose up to 48 hours post end of infusion</time_frame>
    <description>PK: Cmax of LY3461767</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Heart Failure With Reduced Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>LY3461767</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3461767 administered subcutaneously (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered subcutaneously (SC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3461767</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>LY3461767</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are males and in agreement to follow contraceptive requirements, or women of&#xD;
             non-child-bearing potential&#xD;
&#xD;
          -  Have a body mass index (BMI) of &lt; 40.0 kilograms per square meter (kg/m²)&#xD;
&#xD;
          -  Have chronic stable heart failure (New York Heart Association (NYHA) classification II&#xD;
             and III) on guideline directed heart failure therapy for at least 6 months prior to&#xD;
             enrolment&#xD;
&#xD;
          -  Have not changed optimal guideline directed therapy in the last 1 month prior to&#xD;
             screening, If treated with oral diuretics, dose must be stable for at least 2 weeks&#xD;
             prior to screening&#xD;
&#xD;
          -  Have Left Ventricular Ejection Fraction (LVEF) &lt; 40%&#xD;
&#xD;
          -  Have a record of N-terminal pro b-type natriuretic peptide (NT-ProBNP) ≥ 300 picograms&#xD;
             per millilitre (pg/mL)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have myocardial infarction, coronary artery bypass graft surgery or other major&#xD;
             cardiovascular surgery, stroke in the last 90 days prior to screening&#xD;
&#xD;
          -  Have acute decompensated heart failure requiring IV diuretics within 12 weeks prior to&#xD;
             screening&#xD;
&#xD;
          -  Have cardiac amyloidosis, accumulation diseases (e.g., haemochromatosis, Fabry&#xD;
             disease), muscular dystrophies, hypertrophic cardiomyopathy, pericardial constriction,&#xD;
             or complex congenital heart disease.&#xD;
&#xD;
          -  Have any moderate-to-severe stenosis of the mitral and/or aortic valve or moderate-to&#xD;
             severe or greater mitral and/or aortic regurgitation.&#xD;
&#xD;
          -  Have a history or presence of hepatic, pancreatic, or biliary tract disorders&#xD;
&#xD;
          -  Have a history of malignancy or active malignancy at screening.&#xD;
&#xD;
          -  Have not had age-appropriate cancer screening as recommended by the American Cancer&#xD;
             Society and per medical judgment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>313-916-6375</phone>
    </contact>
    <investigator>
      <last_name>David Lanfear</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>314-454-7009</phone>
    </contact>
    <investigator>
      <last_name>Gregory A. Ewald</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina, Division of Cardiology</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>919-843-5223</phone>
    </contact>
    <investigator>
      <last_name>Kirkwood F Adams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sentara Healthcare</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>757-388-2831</phone>
    </contact>
    <investigator>
      <last_name>John Herre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kanagawa Prefectural Hospital Organization Kanagawa Cardiovascular and Respiratory Center</name>
      <address>
        <city>Kanazawa Ward,Yokohama</city>
        <state>Kanagawa</state>
        <zip>236-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81457019581</phone>
    </contact>
    <investigator>
      <last_name>Kazuki Fukui</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81338155411</phone>
    </contact>
    <investigator>
      <last_name>Tatsuya Maruyama</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/1W0ItmrE6ruLINUYr7X1m5</url>
    <description>A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction</description>
  </link>
  <verification_date>November 15, 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

